This is the legacy version of We will be shutting it down on 15 December 2020. Please switch to a supported browser or device. You can see a list of supported browsers in our Help Center. Sep 11
Replying to @Lymenews
Leigner | "62 of 67 patients (92.5%) endorsed net benefit from the received course or courses of disulfiram, combining the low dose group (<4mg/kg/day), the high dose group and the 'cross-over' group."